Eli Lilly


Zuellig Pharma
Concise Prescribing Info
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Monotherapy or in combination w/ methotrexate for active psoriatic arthritis in adults who have responded inadequately to, or who are intolerant to ≥1 disease-modifying anti-rheumatic drug therapies.
Dosage/Direction for Use
SC Plaque psoriasis Recommended dose: 2 inj at wk 0, then 1 inj at wk 2, 4, 6, 8, 10 & 12. Maintenance dose: 1 inj every 4 wk. Psoriatic arthritis Recommended dose: 2 inj at wk 0, then 1 inj every 4 wk thereafter.
Hypersensitivity. Clinically important active infections eg, active TB.
Special Precautions
Hypersensitivity. Not to be given in patients w/ active TB. Increased rate of infections eg, upper resp tract infection, oral candidiasis, conjunctivitis & tinea infections. Patients w/ clinically important chronic infections; inflammatory bowel disease eg, Crohn's disease & ulcerative colitis. Not to be used w/ live vaccines. Renal or hepatic impairment. Women of childbearing potential should use effective contraception during & at least 10 wk after treatment. Avoid use during pregnancy. Lactation. Childn & adolescents ≤2-18 yr. Elderly ≥75 yr.
Adverse Reactions
Upper resp tract infections; inj site reactions. Tinea infection, mucocutaneous herpes simplex; oropharyngeal pain; nausea.
Drug Interactions
CYP450 substrates w/ narrow therapeutic index eg, warfarin.
MIMS Class
ATC Classification
L04AC13 - ixekizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Taltz soln for inj 80 mg/mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in